Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APD421 (Barhemsys) cardiac conduction study in healthy volunteers
NCT03583489Phase 1Completed
- Sponsor
- Acacia Pharma Group Plc
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amisulpride in postoperative nausea and vomiting (PONV) (3 arms), sponsored by Acacia Pharma Group Plc. Primary endpoint: Placebo-corrected change from baseline in QTcF. Started Jul 2018; status: completed.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT03583489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583489.